ULORIC

This brand name is authorized in Canada, United States

Active ingredients

The drug ULORIC contains one active pharmaceutical ingredient (API):

1 Febuxostat UNII 101V0R1N2E - FEBUXOSTAT

Uric acid is the end product of purine metabolism in humans and is generated in the cascade of hypoxanthine → xanthine → uric acid. Both steps in the above transformations are catalyzed by xanthine oxidase (XO). Febuxostat is a 2-arylthiazole derivative that achieves its therapeutic effect of decreasing serum uric acid by selectively inhibiting XO. Read about Febuxostat

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ULORIC Tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
M04AA03	Febuxostat	M Musculo-skeletal system → M04 Antigout preparations → M04A Antigout preparations → M04AA Preparations inhibiting uric acid production
Discover more medicines within M04AA03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02357380
Country: US	FDA, National Drug Code	Identifier(s): 43353-305, 55154-5158, 55154-5159, 64764-677, 64764-918